When a 35-year-old man with essential hypertension was treated with antibiotics for brucellosis his blood pressure rose significantly. While all other treatment was kept constant rifampicin was discontinued. On rechallenge rifampicin did not alter serum concentrations of enalapril or the area under the curve (AUC) between 0 and 7 h, but it did reduce the AUC of the active metabolite enalaprilat by 31%. These observations suggest that there may be an interaction between rifampicin and enalapril, causing reduced hypotensive efficacy of enalapril. The mechanism of such an interaction merits further study, but it could be due to enhanced renal clearance of enalaprilat.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Hichens M, Hand EL, Mulcahy WS (1981) Radioimmunoassay for angiotensin converting enzyme inhibitors. Ligand Q 4: 43
Ohnhaus EE, Kirchhof B, Peheim E (1979) Effect of enzyme induction on plasma lipids using antipyrine, phenobarbital and rifampicin. Clin Pharmacol Ther 25: 591–597
Ulm EH (1983) Enalapril maleate (MK-421), a potent nonsulphhydryl angiotensin-converting enzyme inhibitor: absorption, disposition and metabolism in man. Drug Metab Rev 14: 99–110
About this article
Cite this article
Kandiah, D., Penny, W.J., Fraser, A.G. et al. A possible drug interaction between rifampicin and enalapril. Eur J Clin Pharmacol 35, 431–432 (1988). https://doi.org/10.1007/BF00561378
- drug interaction
- case report